BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35615767)

  • 1. Preliminary Study on Relationship Between Temozolomide Chemotherapy-Resistant Cells and Stem Cells in Gliomas.
    Min X; Dingchao X; Xun Z; Cunzu W
    Turk Neurosurg; 2022; 32(3):357-363. PubMed ID: 35615767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCK1-AS1 Increases Drug Resistance of Glioma Cells to Temozolomide by Modulating miR-137/
    Chen M; Cheng Y; Yuan Z; Wang F; Yang L; Zhao H
    Cancer Biother Radiopharm; 2020 Mar; 35(2):101-108. PubMed ID: 31750728
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.
    Pan Q; Yang XJ; Wang HM; Dong XT; Wang W; Li Y; Li JM
    Cell Biochem Biophys; 2012 Jan; 62(1):185-91. PubMed ID: 21892781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
    Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
    Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N; Zhang Q; Ning B; Luo L; Fang Y
    Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells.
    Zhou D; Wan Y; Xie D; Wang Y; Wei J; Yan Q; Lu P; Mo L; Xie J; Yang S; Qi X
    Exp Mol Med; 2015 Sep; 47(9):e182. PubMed ID: 26337869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple Pathway-Dephosphorylated ASK-1 Confers Temozolomide-Resistance to Human Glioma Cells.
    Gao K; She K; Fan J; Shao L; Ji Z
    Turk Neurosurg; 2024; 34(1):67-73. PubMed ID: 36951032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration of Human U251 Glioma Cells.
    Chernov AN; Filatenkova TA; Glushakov RI; Buntovskaya AS; Alaverdian DA; Tsapieva AN; Kim AV; Fedorov EV; Skliar SS; Matsko MV; Galimova ES; Shamova OV
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization.
    Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J
    Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells.
    Liu N; Hu G; Wang H; Li Z; Guo Z
    J Cell Mol Med; 2018 Nov; 22(11):5300-5310. PubMed ID: 30133120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2-regulated PARP-1 Expression is a Likely Mechanism for the Chemoresistance of Gliomas to Temozolomide.
    Liang Q; Wang B; Zhang C; Song C; Wang J; Sun W; Jiang L; Lin J
    Curr Cancer Drug Targets; 2024; 24(3):328-339. PubMed ID: 37594167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy.
    Ulasov IV; Nandi S; Dey M; Sonabend AM; Lesniak MS
    Mol Med; 2011; 17(1-2):103-12. PubMed ID: 20957337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRPML2 Mucolipin Channels Drive the Response of Glioma Stem Cells to Temozolomide and Affect the Overall Survival in Glioblastoma Patients.
    Morelli MB; Nabissi M; Amantini C; Maggi F; Ricci-Vitiani L; Pallini R; Santoni G
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RNA-binding protein fragile-X mental retardation autosomal 1 (FXR1) modulates glioma cells sensitivity to temozolomide by regulating ferroptosis.
    Wei Y; Duan S; Gong F; Li Q
    Biochem Biophys Res Commun; 2022 May; 603():153-159. PubMed ID: 35294905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma.
    Ding C; Yi X; Chen X; Wu Z; You H; Chen X; Zhang G; Sun Y; Bu X; Wu X; Lin Z; Gu J; Lin Y; Kang D
    J Exp Clin Cancer Res; 2021 May; 40(1):164. PubMed ID: 33975615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 19. Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
    Gong X; Schwartz PH; Linskey ME; Bota DA
    Neurology; 2011 Mar; 76(13):1126-34. PubMed ID: 21346220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.